CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 40 enrolled
Drug / intervention
AZD9977 oral suspension +3 moredrug
Likely dose
Fludrocortisone, tablets 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02532998
NCT02532998Phase 1Completed
CompareCT.gov

A Phase I, Randomized, Single-Blind, Crossover Study to Assess the Pharmacodynamics of AZD9977 Following Single-Dose Administration to Healthy Male Subjects

AstraZeneca·interventional·Posted Aug 26, 2015·Updated Mar 29, 2017

In Brief

A Phase 1 clinical trial evaluating AZD9977 oral suspension, AZD9977 placebo oral suspension, and 2 other interventions for Pharmacodynamics and Healthy Subjects. Completed, enrolled 40 participants across 1 site.

Detailed Summary

This is a Phase I, Randomized, Single-Blind, Crossover Study to Assess the Pharmacodynamics of AZD9977 following Single-Dose administration to healthy male subjects

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPharmacodynamics, Healthy Subjects
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedAug 26, 2015
Enrollment StartSep 1, 2015
Primary CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 10.8 years ago

Interventions

AZD9977 oral suspensiondrug

AZD9977 oral suspension, single dose

AZD9977 placebo oral suspensiondrug

oral suspension, single dose

Fludrocortisone, tabletsdrug

Loading dose of 0.5 mg and maintenance doses of 0.1 mg every second hour up to a total dose of 1.0 mg per treatment period (may be modified to up to 1.3 mg based on emerging data)

Eplerenone, tabletsdrug

100 mg (2 x 50 mg tablets) single dose, may be modified based on emerging data (will not exceed 500 mg per treatment period)